We are a group of motivated immunologists and oncologists committed to delivering the power of cytokines to patients.
Founded in 2017 by leading experts in the field of immunotherapy, Anaveon is a biopharmaceutical company that specializes in the development of treatments for diseases with immune system dysfunction.
Our goal is to harness the power of engineered cytokines and develop novel treatments for diseases with high unmet need.
Years of Experience
Million CHF Funding
Anaveon announces presentation of ANV600 preclinical data supporting combination therapy with therapeutic PD-1 inhibitors
Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on ANV600 at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held from Friday, November 3, 2023, to Sunday, November 5, 2023, in San Diego, California.
Anaveon announces poster presentation at the 2023 European Society for Medical Oncology Annual Meeting
Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on its lead program ANV419 at the European Society of Medical Oncology (ESMO) annual meeting being held from Friday October 20, 2023, to Tuesday, October 24, 2023, in Madrid, Spain.
Anaveon presents clinical trial OMNIA-2 at the American Society of Clinical Oncology 2023 Annual Meeting
Trial in Progress: OMNIA-2, Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma
Anaveon Presents Trial in Progress Data for OMNIA-1 at the American Society of Clinical Oncology 2023 Annual Meeting
OMNIA-1, a Phase I/II study of ANV419, an IL- 2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti-PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma
Our dedicated team of experts has decades of experience in immunology, oncology and drug design. We use our deep knowledge to deliver novel drugs that address unmet medical needs.